Mesirow Institutional Investment Management Inc. Purchases 3,153 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Mesirow Institutional Investment Management Inc. boosted its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 0.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 353,447 shares of the company’s stock after purchasing an additional 3,153 shares during the quarter. Mesirow Institutional Investment Management Inc. owned about 0.72% of Amphastar Pharmaceuticals worth $14,138,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Principal Securities Inc. acquired a new position in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $34,000. YHB Investment Advisors Inc. purchased a new stake in Amphastar Pharmaceuticals during the 1st quarter valued at about $27,000. Quadrant Capital Group LLC lifted its position in Amphastar Pharmaceuticals by 27.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after buying an additional 223 shares in the last quarter. Innealta Capital LLC acquired a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at about $55,000. Finally, Blue Trust Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after buying an additional 309 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Down 3.6 %

AMPH stock opened at $46.98 on Wednesday. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The company has a market cap of $2.30 billion, a P/E ratio of 16.26, a P/E/G ratio of 0.92 and a beta of 0.79. The company’s 50-day moving average price is $42.34 and its 200 day moving average price is $42.96. The company has a current ratio of 3.52, a quick ratio of 2.63 and a debt-to-equity ratio of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.10. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. The business had revenue of $182.39 million during the quarter, compared to analysts’ expectations of $171.29 million. On average, research analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. StockNews.com raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $63.00.

Insider Buying and Selling at Amphastar Pharmaceuticals

In related news, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the completion of the transaction, the director now owns 78,409 shares of the company’s stock, valued at approximately $3,246,132.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Floyd F. Petersen sold 3,000 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $41.40, for a total value of $124,200.00. Following the completion of the sale, the director now owns 78,409 shares in the company, valued at $3,246,132.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Richard K. Prins sold 17,101 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $43.07, for a total value of $736,540.07. Following the transaction, the director now directly owns 33,971 shares in the company, valued at $1,463,130.97. The disclosure for this sale can be found here. Insiders have sold 37,979 shares of company stock valued at $1,656,097 over the last quarter. Corporate insiders own 27.10% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.